IPO Analysis
Himalaya Nutravedics IPO: Price Band, GMP, Lot Size and Full Analysis
Himalaya Nutravedics's ₹26.50 crore SME IPO closes 24 Sept 2026. Price band ₹100–106, 1,200-share lot, GMP flat. Business, risks and our 5.4/10 score.
By Admin
· 4 min read
Himalaya Nutravedics, a nutraceuticals and wellness company, is raising ₹26.50 crore through an SME IPO in a price band of ₹100 to ₹106 per share. The issue opened on 22 September 2026 and closes today, 24 September. Here's a quick rundown before you decide.
Himalaya Nutravedics IPO at a glance
| Detail | Information |
|---|---|
| Issue type | SME |
| Issue size | ₹26.50 crore |
| Price band | ₹100 to ₹106 per share |
| Lot size | 1,200 shares |
| Minimum application | 2 lots (2,400 shares) |
| Minimum investment | ₹2,54,400 (at ₹106) |
| Open date | 22 Sept 2026 |
| Close date | 24 Sept 2026 |
| Allotment date | 25 Sept 2026 |
| Listing date | 29 Sept 2026 |
| Quota | QIB 50% · NII 15% · Retail 35% |
How much can you apply for?
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min = max) | 2 | 2,400 | ₹2,54,400 |
| S-HNI (min) | 3 | 3,600 | ₹3,81,600 |
| S-HNI (max) | 7 | 8,400 | ₹8,90,400 |
| B-HNI (min) | 8 | 9,600 | ₹10,17,600 |
Grey market premium (GMP)
The GMP for Himalaya Nutravedics is ₹0, so the estimated listing price is ₹106, flat to the upper price band. Based on current subscription figures, the estimated allotment chance is 100% across retail, S-HNI and B-HNI. The issue isn't heavily oversubscribed, which also explains the muted grey market.
About the company
Himalaya Nutravedics works in nutraceuticals and health and wellness products. That market is growing as consumers move towards natural and health-enhancing products. According to IPO Milega's analysis:
- The management team has an average of about 15 years of industry experience.
- Two major expansions have been completed, including entry into three new markets in the last two years.
- Market share rose about 15% over the past year.
- Revenue has been stable, with steady growth over the last three years.
- The product range is limited. The company concentrates on its core offerings.
Financial highlights
We couldn't access detailed financial statements (revenue, profit, debt, ratios), so the financials score is 1/10. That reflects missing data, not necessarily weak numbers. Read the prospectus for the audited figures before applying.
Strengths
- A sector tailwind. Nutraceuticals and wellness are among the fastest-growing consumer categories in India.
- Experienced management with a record of expansion.
- Rising market share and entry into new markets.
- Favourable timing. The issue lands while investors are interested in health-focused businesses.
Risks to watch
- Supplier dependence. It relies heavily on a few key suppliers, and supply-chain disruptions could hit operations.
- Regulatory risk. Nutraceuticals are tightly regulated by FSSAI and other bodies, and rule changes could affect the business.
- Litigation. Ongoing litigation could affect financial stability.
- Intense competition from both large FMCG brands and new D2C players.
- Limited financial disclosure in the data available to us.
- The high SME ticket size. The minimum investment of about ₹2.54 lakh comes with lower liquidity after listing.
IPO Milega score: 5.4 / 10 (Moderate)
| Parameter | Score |
|---|---|
| Financials | 1.0 (data not available) |
| Risk (higher = safer) | 5.0 |
| Performance | 7.0 |
| Flexibility | 7.0 |
| Timing | 7.0 (Favourable) |
| Overall | 5.4 |
The profitability of allotment scores 5/10.
Our take
Himalaya Nutravedics is in an attractive, growing sector and has an experienced team. However, the flat GMP, limited financial data and a large minimum ticket make it a wait-and-watch issue for most retail investors. If you're considering it, check the prospectus financials and the final-day subscription numbers first.
👉 See the live GMP, subscription status and allotment chances on IPO Milega.
Disclaimer: This article is for information and education only. It is not investment advice or a recommendation to buy or sell any security. SME IPOs carry higher risk and lower liquidity. Please read the prospectus and consult a SEBI-registered advisor before investing. GMP is unofficial and can change quickly.